UB Paderborn / Katalog / Suche / in CDI

Immune-mediated thrombotic thrombocytopenic purpura following administration of Pfizer-BioNTech COVID-19 vaccine

Haematologica (Roma), 2022-04, Vol.107 (4), p.1008

2022

Link zum Volltext

Verfügbarkeit prüfen

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives

Annals of hematology, 2022-05, Vol.101 (5), p.963-978

2022

Link zum Volltext

Verfügbarkeit prüfen

Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review

Orphanet journal of rare diseases, 2023-02, Vol.18 (1), p.27-27, Article 27

2023

Link zum Volltext

Verfügbarkeit prüfen

ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission

Haematologica (Roma), 2008-02, Vol.93 (2), p.232-239

2008

Link zum Volltext

Verfügbarkeit prüfen

Immune thrombocytopenic purpura cases following COVID-19 vaccination

Mediterranean journal of hematology and infectious diseases, 2021-06, Vol.13 (1), p.e2021047-e2021047

2021

Link zum Volltext

Verfügbarkeit prüfen

A rare case of acquired factor V inhibitor, during treatment with dabigatran for chronic atrial fibrillation, successfully treated with bypassing agents

Clinical case reports, 2021-02, Vol.9 (2), p.623-628

2021

Link zum Volltext

Verfügbarkeit prüfen

Parkinson's disease in Gaucher disease patients: what's changing in the counseling and management of patients and their relatives?

Orphanet journal of rare diseases, 2020-09, Vol.15 (1), p.262-262, Article 262

2020

Link zum Volltext

Verfügbarkeit prüfen

Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits

Frontiers in medicine, 2019-12, Vol.6, p.261-261

2019

Link zum Volltext

Verfügbarkeit prüfen

Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future

Journal of clinical medicine, 2023-03, Vol.12 (6), p.2188

2023

Link zum Volltext

Verfügbarkeit prüfen

Acquired hemophilia in a 7‐year‐old girl successfully treated with recombinant FVIIA and steroids: A case report

Clinical case reports, 2021-02, Vol.9 (2), p.638-643

2021

Link zum Volltext

Verfügbarkeit prüfen

Gaucher Disease or Acid Sphingomyelinase Deficiency? The Importance of Differential Diagnosis

Journal of clinical medicine, 2024-03, Vol.13 (5), p.1487

2024

Link zum Volltext

Verfügbarkeit prüfen

Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations

Therapeutic advances in hematology, 2021, Vol.12, p.20406207211048361-20406207211048361

2021

Link zum Volltext

Verfügbarkeit prüfen

Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports

Hematology reports, 2023-05, Vol.15 (2), p.317-324

2023

Link zum Volltext

Verfügbarkeit prüfen

Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973)

Journal of clinical medicine, 2022-06, Vol.11 (12), p.3434

2022

Link zum Volltext

Verfügbarkeit prüfen

A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents

Journal of clinical medicine, 2020-09, Vol.9 (9), p.2876

2020

Link zum Volltext

Verfügbarkeit prüfen

Focus on Key Issues in Immune Thrombotic Thrombocytopenic Purpura: Italian Experience of Six Centers

Journal of clinical medicine, 2021-12, Vol.10 (23), p.5702

2021

Link zum Volltext

Verfügbarkeit prüfen

The HLA Variant rs6903608 Is Associated with Disease Onset and Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Caucasians

Journal of clinical medicine, 2020-10, Vol.9 (10), p.3379

2020

Link zum Volltext

Verfügbarkeit prüfen

Use of Emicizumab in Patients with Hemophilia a with and without Inhibitors: A Single Center Experience

Blood, 2021-11, Vol.138 (Supplement 1), p.4248-4248

2021

Link zum Volltext

Verfügbarkeit prüfen

Bone turnover markers in patients with type 1 Gaucher disease

Hematology reports, 2012-11, Vol.4 (4), p.e21-e21

2012

Link zum Volltext

Verfügbarkeit prüfen

Long-term bone outcomes in Italian patients with Gaucher disease type 1 or type 3 treated with imiglucerase: A sub-study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry

Blood cells, molecules, & diseases, 2023-01, Vol.98, p.102705-102705, Article 102705

2023

Link zum Volltext

Verfügbarkeit prüfen

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

The New England journal of medicine, 2016-02, Vol.374 (6), p.511-522

2016

Link zum Volltext

Verfügbarkeit prüfen

Reference ranges for biventricular volumes and ejection fraction and for left ventricular mass in adult thalassemia intermedia patients without myocardial iron overload

Journal of cardiovascular magnetic resonance, 2013-01, Vol.15 (Suppl 1), p.P102-P102, Article P102

2013

Link zum Volltext

Verfügbarkeit prüfen

Similarities and differences between Gaucher disease and acid sphingomyelinase deficiency: An algorithm to support the diagnosis

European journal of internal medicine, 2023-02, Vol.108, p.81-84

2023

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness and Safety of Eliglustat Treatment in Gaucher Disease: Real-Life Unicentric Experience

Clinical therapeutics, 2023-11, Vol.45 (11), p.1105-1110

2023

Link zum Volltext

Verfügbarkeit prüfen

VTE Incidence in RRMM Patients Treated with NOVEL Agents: A Monocentric Real Life Experience

Blood, 2019-11, Vol.134 (Supplement_1), p.4972-4972

2019

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Immune-mediated thrombotic thrombocytopenic purpura following administration of Pfizer-BioNTech COVID-19 vaccine

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives

Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review

ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission

Immune thrombocytopenic purpura cases following COVID-19 vaccination

A rare case of acquired factor V inhibitor, during treatment with dabigatran for chronic atrial fibrillation, successfully treated with bypassing agents

Parkinson's disease in Gaucher disease patients: what's changing in the counseling and management of patients and their relatives?

Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits

Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future

Acquired hemophilia in a 7‐year‐old girl successfully treated with recombinant FVIIA and steroids: A case report

Gaucher Disease or Acid Sphingomyelinase Deficiency? The Importance of Differential Diagnosis

Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations

Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports

Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973)

A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents

Focus on Key Issues in Immune Thrombotic Thrombocytopenic Purpura: Italian Experience of Six Centers

The HLA Variant rs6903608 Is Associated with Disease Onset and Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Caucasians

Use of Emicizumab in Patients with Hemophilia a with and without Inhibitors: A Single Center Experience

Bone turnover markers in patients with type 1 Gaucher disease

Long-term bone outcomes in Italian patients with Gaucher disease type 1 or type 3 treated with imiglucerase: A sub-study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

Reference ranges for biventricular volumes and ejection fraction and for left ventricular mass in adult thalassemia intermedia patients without myocardial iron overload

Similarities and differences between Gaucher disease and acid sphingomyelinase deficiency: An algorithm to support the diagnosis

Effectiveness and Safety of Eliglustat Treatment in Gaucher Disease: Real-Life Unicentric Experience

VTE Incidence in RRMM Patients Treated with NOVEL Agents: A Monocentric Real Life Experience

Suchergebnisse filtern